Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Multiple Sclerosis

Free Subscription Articles published in Can J Neurol Sci Retrieve available abstracts of 14 articles: HTML format

Single Articles

June 2025
1. FREEDMAN MS, Clift F, Devonshire V, Emond F, et al
   First-line use of higher-efficacy disease-modifying therapies in multiple sclerosis: Canadian consensus recommendations.
   Can J Neurol Sci. 2025 Jun 9:1-28. doi: 10.1017/cjn.2025.10342.
   PubMed    
   
   
   May 2025
2. FREEDMAN DE, Sundaram ANE, Oh J, Feinstein A, et al
   How does time of testing influence cognitive performance in multiple sclerosis?
   Can J Neurol Sci. 2025 May 19:1-7. doi: 10.1017/cjn.2025.10125.
   PubMed    
   
   
   March 2025
3. FIFIELD KE, Fudge NJ, Arsenault ST, Anthony S, et al
   An overview of multiple sclerosis care in rural and urban Newfoundland and Labrador.
   Can J Neurol Sci. 2025 Mar 12:1-25. doi: 10.1017/cjn.2025.
   PubMed    
   
   
   
4. NATHOO N, Clark WI, Robinson R, Jarvis S, et al
   Indigenous Peoples Living with Multiple Sclerosis in Canada.
   Can J Neurol Sci. 2025 Mar 4:1-14. doi: 10.1017/cjn.2025.
   PubMed    
   
   
   
5. GUILLEMETTE A, Roberge D, Menard C, Bahary JP, et al
   Outcomes of CyberKnife Radiosurgery for Trigeminal Neuralgia in Patients with Multiple Sclerosis.
   Can J Neurol Sci. 2025 Mar 3:1-22. doi: 10.1017/cjn.2025.
   PubMed    
   
   
   November 2024
6. SA'DI Q, Alsmadi S, Shtaiyat W, Qasaimeh M, et al
   FLVCR1 Gene Mutation in a Patient with an Atypical Multiple Sclerosis-Like Presentation.
   Can J Neurol Sci. 2024 Nov 27:1-12. doi: 10.1017/cjn.2024.
   PubMed    
   
   
   
7. GONCUOGLU C, Acar-Ozen P, Kasikci M, Tuncer A, et al
   Pharmacist-implemented self-management module in multiple sclerosis patients: A randomized controlled trial.
   Can J Neurol Sci. 2024 Nov 13:1-27. doi: 10.1017/cjn.2024.
   PubMed    
   
   
   October 2024
8. MCCOMBE JA, Smyth P, Kate M, So H, et al
   Healthcare Cost of Multiple Sclerosis and in Relation to Disability Level in Alberta.
   Can J Neurol Sci. 2024 Oct 2:1-12. doi: 10.1017/cjn.2024.
   PubMed     Abstract available
   
   
   May 2024
9. OH J, Bhan V, Traboulsee A, Morrow SA, et al
   Health Canada drug approval process: a barrier to personalized care in multiple sclerosis.
   Can J Neurol Sci. 2024 May 23:1-12. doi: 10.1017/cjn.2024.
   PubMed    
   
   
   April 2024
10. BALCOM EF, McCombe JA, Kate M, Vu K, et al
    Geographical variation in medication and health resource use in multiple sclerosis.
    Can J Neurol Sci. 2024 Apr 11:1-21. doi: 10.1017/cjn.2024.
    PubMed    
    
    
    February 2024
11. NOBILE S, Beauchemin P
    Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort.
    Can J Neurol Sci. 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.
    PubMed    
    
    
    November 2023
12. HANDZIC A, Margolin E
    Myelin Oligodendrocyte Glycoprotein-related isolated internuclear ophthalmoplegia mimicking multiple sclerosis.
    Can J Neurol Sci. 2023 Nov 7:1-5. doi: 10.1017/cjn.2023.
    PubMed    
    
    
    September 2023
13. DHAR D, Kamble N, Pal PK
    Long Latency Reflexes in Clinical Neurology: A Systematic Review.
    Can J Neurol Sci. 2023;50:751-763.
    PubMed     Abstract available
    
    
    April 2023
14. GIACOMINI PS, Oh J, Morrow SA, Beauchemin P, et al
    Virtual management of multiple sclerosis: providing access or just phoning it in?
    Can J Neurol Sci. 2023 Apr 17:1-11. doi: 10.1017/cjn.2023.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.